Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas
Pediatric Radiology, 06/25/2012
Karmazyn B et al. – Bone marrow signal changes (BMSC) appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow–up, BMSC often showed a decrease without complications.



